Dr Reddy’s’ settles case with Bristol Myers Squibb unit over nonexclusive malignant growth drug Kumar Jeetendra | September 17, 2020 The Hyderabad-based firm has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, Dr Reddy”s Laboratories said in a statement. In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a permit to sell volume-limited amounts of generic lenalidomide capsules in america starting on a confidential …
WHO says specialists examining new COVID-19 variant in England Kumar Jeetendra | December 15, 2020 Myth 1: Mental illnesses are rare | On October 7, the World Health Organization said “close to one billion people globally have a mental disorder”. (Image: Reuters) The World Health Organization is aware of a new variant of COVID-19 that has emerged in Britain, but there is no evidence the strain behaves differently to existing …
Cipla Launches ‘RT Direct’ Multiplex real time PCR kit for Covid-19 RNA extraction free kit to deliver results in just 45 Min Kumar Jeetendra | May 10, 2022 Mumbai, India; May 10, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced the commercialisation of ‘RT-Direct’ multiplex COVID-19 RT PCR Test kit in India, in partnership with Genes2Me Pvt. Ltd. With this, Cipla is expanding its diagnostics offering to bring more advanced and innovative products. Cipla will be responsible …
Cipla & Formosa Ink Licensing Deal for Clobetasol Suspension Kumar Jeetendra | March 18, 2025 Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals (6838.TW) for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007). Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain following ocular surgery across 11 countries …
